Ascendis Pharma

Ascendis Pharma A/S is a global biopharmaceutical company dedicated to developing innovative therapies that address critical unmet medical needs and enhance patient outcomes. The company's core strength lies in its proprietary TransCon® technology platform, designed to create novel treatments with potentially superior safety, efficacy, tolerability, and convenience profiles. Ascendis Pharma focuses its pipeline on rare endocrinology diseases and other serious conditions, with a portfolio of commercial products and candidates progressing through clinical development stages worldwide. Founded in 2007, the company operates with a significant international footprint, employing between 1,000 and 5,000 individuals across its global operations. Meet Ascendis Pharma's team to gain insight into the expertise driving their therapeutic advancements. The company maintains additional facilities and offices strategically located throughout Europe and the United States, underscoring its commitment to global reach and accessibility in its research and development efforts. Ascendis Pharma's financial performance is robust, reporting revenue of $755.6M. As a publicly traded entity on NASDAQ under the ticker ASND, the company is positioned for continued growth and innovation in the biopharmaceutical sector. Explore financial highlights for a detailed overview of their fiscal performance and investment in groundbreaking medical solutions.